The Therapy Acceleration Program® (TAP) identifies and funds innovative projects related to therapies, supportive care or diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.
TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain the resources they need or a partner to complete the testing, registration and marketing of new treatments, supportive care and diagnostics for leukemia, lymphoma and myeloma.
Affimed has initiated a phase 2a clinical trial (NCT02321592) in Hodgkin lymphoma, or HL for its lead candidate, AFM13, a bispecific CD30/CD16A TandAb antibody, with first data expected in late 2015 and final data expected in the second half of 2016. Affimed is preparing an additional phase 1b/2a investigator-initiated trial with AFM13 in CD30-positive lymphoma as well as a phase 1b trial with AFM13 in combination with a checkpoint modulator. Initial evidence of the synergistic effect of AFM13 in combination with checkpoint modulators will be presented at the upcoming ASCO 2015 Annual Meeting.
Researchers at Johns Hopkins announced significant findings in Science Translational Medicine about a novel approach to immunotherapy to treat patients with myeloma. A Phase 2 study (NCT01858558) is currently enrolling and is being supported through the Therapy Acceleration Program.
Nanosyn and The Leukemia & Lymphoma Society Announce Achieving a Significant Milestone in Developing New Therapies for MLL Leukemia
Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan
Clinical Trials in Partnership with LLS
Both TAP and LLS research grant fundings are critical in supporting many active clinical trials at any given time. The ClinicalTrials.gov website provides an updated listing of clinical trials where LLS is listed as a collaborator. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. More information about the clinical trials in partnership with LLS TAP can also be found within each TAP division found below.
How TAP Works
The program comprises three divisions, each with designated strategies, to speed the development of blood cancer treatments, supportive care and diagnostics: